COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03430843
Recruitment Status : Active, not recruiting
First Posted : February 13, 2018
Last Update Posted : March 19, 2020
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Condition or disease Intervention/treatment Phase
Esophageal Squamous Cell Carcinoma (ESCC) Drug: Tislelizumab Drug: Paclitaxel, or Docetaxel, or Irinotecan Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 513 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma
Actual Study Start Date : January 26, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tislelizumab
Tislelzumab will be administered with 200 mg intravenous dosing (IV) on Day1, given every 21 days.
Drug: Tislelizumab
Other Name: BGB-A317

Active Comparator: Investigator chosen chemotherapy

Paclitaxel will be administered at a dose of 135-175 mg /m² IV, Day 1, given every 21 days or 80-100mg/m2 IV given on a weekly schedule.

OR docetaxel will be administered at a dose of 75 mg/m2 IV, Day 1, given 21 days.

OR irinotecan will be administered at a dose of 125mg/m2 IV, Day 1, 8, given 21 days.

Drug: Paclitaxel, or Docetaxel, or Irinotecan
One of the following three single-agent chemotherapies as determined by the Investigator Paclitaxel, or Docetaxel, or Irinotecan

Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: approximately 2 years from date of first randomization ]
    Length of time from study treatment initiation to death of any cause

Secondary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: 2 years ]
    Clinical response rate of treatment (CR + PR) according to RECIST v1.1 criteria

  2. Progression-free survival (PFS) [ Time Frame: 2 years ]
    The interval from study treatment initiation until the determination of disease progression according to RECIST v1.1 criteria or death

  3. Duration of response (DOR) [ Time Frame: 2 years ]
    The interval from the date of the first response (complete response or partial response) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause

  4. The Health-Related Quality of Life Questionnaire [ Time Frame: 2 years ]
  5. Safety will be analyzed through the incidence of adverse events. [ Time Frame: From the first dose date to 30 days after the last dose date ]
  6. Safety will be analyzed through the incidence of immune-related adverse events. [ Time Frame: From the first dose date to 90 days after the last dose date ]
  7. Safety will be analyzed through the incidence of serious adverse events. [ Time Frame: From the first dose date to 30 days after the last dose date ]
  8. Safety will be analyzed through the incidence of laboratory abnormalities. [ Time Frame: From the first dose date to 30 days after the last dose date ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
  2. Tumor progression during or after first-line treatment for advanced unresectable / metastatic ESCC
  3. At least one measurable/evaluable lesion by RECIST v1.1
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to randomization
  5. Adequate End organ function

Key Exclusion Criteria:

  1. Receipt of 2 or more prior systemic treatments for advanced/metastatic unresectable ESCC
  2. History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to randomization
  3. Apparent tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigator
  4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
  5. Received prior therapies targeting PD-1 or PD-L1
  6. Prior malignancy active within the previous 2 years (exceptions include the tumor under investigation in this trial, and locally recurring cancers that have undergone curative treatment, such as resected basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast)
  7. Active brain or leptomeningeal metastasis.
  8. Has active autoimmune disease or history of autoimmune diseases at high risk for relapse
  9. Known history of, or any evidence of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc
  10. Known history of Human Immunodeficiency Virus (HIV)
  11. Has cardiovascular risk factors
  12. Pregnant or breastfeeding woman.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03430843

Show Show 131 study locations
Sponsors and Collaborators
Layout table for investigator information
Study Director: Virginia Paton, Pharm.D. BeiGene
Layout table for additonal information
Responsible Party: BeiGene Identifier: NCT03430843    
Other Study ID Numbers: BGB-A317-302
2017-003699-30 ( EudraCT Number )
CTR20171026 ( Registry Identifier: Center for drug evaluation, CFDA )
First Posted: February 13, 2018    Key Record Dates
Last Update Posted: March 19, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BeiGene:
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Squamous Cell
Esophageal Squamous Cell Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors